372 institutions hold shares in Ultragenyx Pharmaceutical Inc. (RARE), with 3.59M shares held by insiders accounting for 5.36% while institutional investors hold 108.70% of the company’s shares. The shares outstanding are 64.69M, and float is at 63.41M with Short Float at 8.73%. Institutions hold 102.88% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Price (T.Rowe) Associates Inc with over 9.47 million shares valued at $1.31 billion. The investor’s holdings represent 14.15% of the RARE Shares outstanding. As of Dec 30, 2020, the second largest holder is Capital Research Global Investors with 7.26 million shares valued at $1.01 billion to account for 10.85% of the shares outstanding. The other top investors are Capital International Investors which holds 6.26 million shares representing 9.35% and valued at over $866.75 million, while Vanguard Group, Inc. (The) holds 8.44% of the shares totaling 5.65 million with a market value of $782.18 million.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is -21.12% lower on its value in year-to-date trading and has touched a low of $48.50 and a high of $179.65 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RARE stock was last observed hovering at around $113.42 in the last trading session, with the day’s loss setting it -4.23% off its average median price target of $167.00 for the next 12 months. It is also 44.01% off the consensus price target high of $195.00 offered by 17 analysts, but current levels are -10.29% lower than the price target low of $99.00 for the same period.
Currently trading at $109.19, the stock is -8.07% and -18.84% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.7 million and changing -3.73% at the moment leaves the stock -1.24% off its SMA200. RARE registered 126.07% gain for a year compared to 6-month gain of 29.37%. The firm has a 50-day simple moving average (SMA 50) of $127.00 and a 200-day simple moving average (SMA200) of $124.08.
The stock witnessed a -7.86% loss in the last 1 month and extending the period to 3 months gives it a -19.99%, and is 2.14% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.54% over the week and 6.34% over the month.
Ultragenyx Pharmaceutical Inc. (RARE) has around 893 employees, a market worth around $7.35B and $271.00M in sales. Profit margin for the company is -68.80%. Distance from 52-week low is 125.13% and -39.22% from its 52-week high. The company has generated returns on investments over the last 12 months (-28.70%).
Ultragenyx Pharmaceutical Inc. (RARE) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Ultragenyx Pharmaceutical Inc. (RARE) is a “Overweight”. 17 analysts offering their recommendations for the stock have an average rating of 2.20, where 8 rate it as a Hold and 0 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Ultragenyx Pharmaceutical Inc. is expected to release its quarterly report on 08/05/2021 and quarterly earnings per share for the current quarter are estimated at -$1.22 with sales reaching $77.11M over the same period.The EPS is expected to grow by 56.90% this year, but quarterly earnings will post 24.00% year-over-year. Quarterly sales are estimated to grow 112.40% in year-over-year returns.
Ultragenyx Pharmaceutical Inc. (RARE) Insider Activity
A total of 57 insider transactions have happened at Ultragenyx Pharmaceutical Inc. (RARE) in the last six months, with sales accounting for 34 and purchases happening 23 times. The most recent transaction is an insider sale by Huizenga Theodore Alan, the company’s SVP, Controller and PAO. SEC filings show that Huizenga Theodore Alan sold 3,000 shares of the company’s common stock on Mar 08 at a price of $120.69 per share for a total of $0.36 million. Following the sale, the insider now owns 13544.0 shares.
Ultragenyx Pharmaceutical Inc. disclosed in a document filed with the SEC on Mar 02 that Harris Erik (EVP & Chief Commercial Officer) sold a total of 707 shares of the company’s common stock. The trade occurred on Mar 02 and was made at $138.16 per share for $97679.0. Following the transaction, the insider now directly holds 27813.0 shares of the RARE stock.
Still, SEC filings show that on Mar 01, Kassberg Thomas Richard (CBO & EVP) disposed off 4,572 shares at an average price of $138.17 for $0.63 million. The insider now directly holds 107,181 shares of Ultragenyx Pharmaceutical Inc. (RARE).
Ultragenyx Pharmaceutical Inc. (RARE): Who are the competitors?
The company’s main competitors (and peers) include Amicus Therapeutics Inc. (FOLD) that is trading 2.47% up over the past 12 months and BioMarin Pharmaceutical Inc. (BMRN) that is -6.90% lower over the same period. Albireo Pharma Inc. (ALBO) is 116.96% up on the 1-year trading charts. Short interest in the company’s stock has risen 4.15% from the last report on Feb 11, 2021 to stand at a total of 5.31 million short shares sold with a short interest ratio of 13.38.